Close

Jefferies Assumes Aclaris Therapeutis (ACRS) at Buy

July 23, 2021 7:49 AM EDT Send to a Friend
Jefferies analyst Roger Song assumes coverage on Aclaris Therapeutis (NASDAQ: ACRS) with a Buy rating and a price target of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login